Ariad Pharmaceuticals Inc Credit Suisse reiterates Neutral rating, price target raised to $8 from $5
- Firms new post-relaunch survey suggests that physicians view Iclusig as an essential drug for CML patients with T315I or other mutations, or for patients that have failed multiple agents. That said, doctors have become more cautious on the adverse event profile for the drug following the marketing suspension.
- While use is certainly going to be more restricted than initial expectations, firms findings make them incrementally more positive relative to their ber bearish view after FDA removed Iclusig from the market.
- While use is certainly going to be more restricted than initial expectations, firms findings make them incrementally more positive relative to their ber bearish view after FDA removed Iclusig from the market.